Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial.

August 29, 2026| Source: JAMA

Pulmonary vein isolation (PVI) is less effective in persistent than in paroxysmal atrial fibrillation (AF). To determine whether adding posterior left atrial wall isolation (PWI) to pulsed field ablation (PFA)-based PVI reduces atrial tachyarrhythmia in patients with persistent AF. This investigator-initiated, multicenter, randomized superiority trial with blinded end-point adjudication was conducted at 6 centers in Switzerland. Patients with symptomatic, persistent AF were enrolled from November 2023 to February 2025, with 1-year follow-up completed February 2026. Patients were randomized 1:1 to PFA-based PVI with PWI vs PFA-based PVI alone. All patients received an implantable cardiac monitor (ICM) after ablation. The primary end point was first recurrence of atrial tachyarrhythmia during days 91 to 365 after ablation, detected by continuous ICM monitoring and adjudicated by an independent clinical events committee blinded to treatment allocation. There were 29 secondary end points, including atrial arrhythmia burden during days 91 to 365, time to arrhythmia recurrence during days 91 to 365 using different minimum episode durations, and a safety composite, which comprised cardiac tamponade requiring drainage, persistent phrenic nerve palsy lasting more than 24 hours, serious vascular complications requiring intervention, stroke or transient ischemic attack, atrioesophageal fistula, or death up to day 90. Among 206 randomized patients (mean [SD] age, 65.8 [9.2] years; 165 [80.1%] males; 102 randomized to PVI with PWI; 104 randomized to PVI alone), atrial tachyarrhythmia recurred in 51 of 102 patients (50.6%) assigned to PVI with PWI and in 63 of 104 patients (60.6%) assigned to PVI alone (rate ratio [RR], 0.75 [95% CI, 0.51-1.09]; P = .13). Of the 29 prespecified secondary outcomes, 22 were not significantly different. The mean atrial arrhythmia burden was 6.9% and 11.0%, respectively (difference, -4.1 percentage points; 95% CI, -8.0 to -0.2 percentage points; P = .04). Across minimum episode durations of 1 hour or longer, 6 hours or longer, 1 day or longer, 2 days or longer, and 7 days or longer, RRs for PVI with PWI vs PVI alone were 0.64 (95% CI, 0.41-0.99), 0.62 (95% CI, 0.38-1.03), 0.37 (95% CI, 0.18-0.78), 0.40 (95% CI, 0.18-0.88), and 0.51 (95% CI, 0.22-1.23), respectively. The safety composite end point occurred in 2 patients assigned to PVI with PWI. In patients with persistent AF, adding PFA-based PWI to PVI did not significantly reduce atrial tachyarrhythmia recurrence lasting 30 seconds or longer compared with PVI alone. The findings for secondary end points are hypothesis generating and warrant further evaluation in a larger trial. ClinicalTrials.gov Identifier: NCT05986526.

Read the original source →

The honey bee stinger: An unusual pump with collapsible double pistons.

Most stinging animals deliver venom by contracting muscles around a venom reservoir, but honey bees employ a fundamentally different strategy. The stingers of worker bees have the unique ability to autotomize, separating from the body, to continue to sting independently. Despite more than a century of anatomical descriptions, the mechanics of venom pumping have remained unresolved due to the challenges of observing them in action. We recorded high-speed videos of active, autotomized stingers, co

Chronic cigarette smoke exposure induces distinct stem cell states driving genetic driver-specific non-small cell lung cancer subtypes.

Cigarette smoke-induced chronic inflammation (CI) potentiates development of non-small cell lung cancer (NSCLC) by mediating genetic and epigenetic events. Using normal lung organoids (LOs), we define how chronic cigarette smoke condensate (CSC) exposure drives two separate stem cell populations to evolve premalignant states harboring progressive epigenetic and linked transcriptomic abnormalities in the absence of major driver mutations. These dynamics facilitate evolution of an immune evasive s

Cell identity competes with surface tension to determine stromal organization in tumor spheroids beyond the CAF shell paradigm.

Cancer-associated fibroblasts (CAFs) are often found forming a peripheral stromal barrier around tumors. Here, this paradigm is challenged using microfabricated 3D cancer-CAF spheroid models combined with quantitative magnetic force tensiometry. A surface tension atlas is established for eight cancer cell lines, three CAF populations, and heterotypic tumor-CAF assemblies, spanning nearly two orders of magnitude. Surface tension is first shown to govern spheroid morphology and modulate drug respo

A phenome-wide structural variant map from 467,152 UK Biobank genomes.

Structural variants (SVs) are large (>50 base pairs) genomic rearrangements that can significantly influence human phenotypes, yet their contribution to health and disease remains undercharacterized. We conducted a phenome-wide association study (PheWAS) of 1.6 million SVs identified in whole-genome sequencing data from 467,152 UK Biobank participants, across 13,322 binary, 2,018 quantitative, and 2,923 plasma protein traits. Of these, 82.25% of SVs were outside the detectable range of prior

Mitochondria-targeted tetraoxanes initiate lipid peroxidation to drive ferroptosis and tumor suppression.

Ferroptosis is implicated as a vulnerability in multiple cancers, yet approaches for effectively inducing ferroptosis in vivo are limited. Bypassing conventional strategies targeting the antiferroptotic glutathione peroxidase 4 (GPX4) and ferroptosis suppressor protein 1 (FSP1) proteins, we designed metabolic initiators of lipid peroxidation (MILPOs) and developed the compounds WMK-1/2, which contain tetraoxane radical-generating and mitochondria-targeting groups, as de novo ferroptosis inducers